NCT05993806View on ClinicalTrials.gov

A Bioequivalence Study of L04TD3 Compared to Administration of L04RD1 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 2, 2023

Primary Completion Date

June 12, 2023

Study Completion Date

June 29, 2023

Conditions
Essential Hypertension
Interventions
DRUG

L04RD1

1 tablet of L04RD1

DRUG

L04TD3

1 tablet of L04TD3

Trial Locations (1)

08756

H plus Yangji Hospital, Seoul

Sponsors

Lead Sponsor

Celltrion
All Listed Sponsors
lead

Celltrion

INDUSTRY

NCT05993806 - A Bioequivalence Study of L04TD3 Compared to Administration of L04RD1 in Healthy Volunteers | Biotech Hunter | Biotech Hunter